These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 19098860)

  • 1. Pilot study on the effect of linaclotide in patients with chronic constipation.
    Johnston JM; Kurtz CB; Drossman DA; Lembo AJ; Jeglinski BI; MacDougall JE; Antonelli SM; Currie MG
    Am J Gastroenterol; 2009 Jan; 104(1):125-32. PubMed ID: 19098860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of linaclotide for patients with chronic constipation.
    Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
    Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
    Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
    Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study.
    Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B
    Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
    Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
    J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.
    Lacy BE; Schey R; Shiff SJ; Lavins BJ; Fox SM; Jia XD; Blakesley RE; Hao X; Cronin JA; Currie MG; Kurtz CB; Johnston JM; Lembo AJ
    PLoS One; 2015; 10(7):e0134349. PubMed ID: 26222318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two randomized trials of linaclotide for chronic constipation.
    Lembo AJ; Schneier HA; Shiff SJ; Kurtz CB; MacDougall JE; Jia XD; Shao JZ; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Eng P; Fox SM; Johnston JM
    N Engl J Med; 2011 Aug; 365(6):527-36. PubMed ID: 21830967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
    Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
    Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
    Quigley EM; Vandeplassche L; Kerstens R; Ausma J
    Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Schoenfeld P; Lacy BE; Chey WD; Lembo AJ; Kurtz CB; Reasner DS; Bochenek W; Tripp K; Currie MG; Fox SM; Blakesley RE; OʼDea CR; Omniewski ND; Hall ML
    Am J Gastroenterol; 2018 Jan; 113(1):105-114. PubMed ID: 29091082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
    Johnston JM; Shiff SJ; Quigley EM
    Curr Med Res Opin; 2013 Feb; 29(2):149-60. PubMed ID: 23198977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
    Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
    Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.
    Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Hayashi K; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
    Neurogastroenterol Motil; 2019 Jan; 31(1):e13487. PubMed ID: 30353619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
    Johnston JM; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; O'Dea C; Baird M; Lembo AJ
    Gastroenterology; 2010 Dec; 139(6):1877-1886.e2. PubMed ID: 20801122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
    Rao SS; Quigley EM; Shiff SJ; Lavins BJ; Kurtz CB; MacDougall JE; Currie MG; Johnston JM
    Clin Gastroenterol Hepatol; 2014 Apr; 12(4):616-23. PubMed ID: 24075889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.